Lataa...
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin–angiotensin system reduces the risk of kidney disease progression and treatments that...
Tallennettuna:
| Julkaisussa: | Clin Kidney J |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6275453/ https://ncbi.nlm.nih.gov/pubmed/30524708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy090 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|